Tsukuba, Japan

Atsumi Yamaguchi

USPTO Granted Patents = 4 

 


Average Co-Inventor Count = 9.3

ph-index = 2

Forward Citations = 172(Granted Patents)


Location History:

  • Ibaraki, JP (1999)
  • Tsukuba, JP (2007 - 2022)

Company Filing History:


Years Active: 1999-2022

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Atsumi Yamaguchi

Introduction

Atsumi Yamaguchi is a prominent inventor based in Tsukuba, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic agents. With a total of four patents to her name, Yamaguchi's work has the potential to impact the treatment of serious health conditions.

Latest Patents

Yamaguchi's latest patents include a therapeutic agent for hepatocellular carcinoma. This agent comprises a specific compound, 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof. Additionally, she has developed nitrogen-containing aromatic derivatives, which are represented by a complex general formula involving various heterocyclic groups and substituents.

Career Highlights

Throughout her career, Atsumi Yamaguchi has worked with notable companies in the pharmaceutical industry, including Eisai Company, Limited and Eisai R&D Management Co., Ltd. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research.

Collaborations

Yamaguchi has collaborated with esteemed colleagues such as Katsuji Nakamura and Yasuhiro Funahashi. These partnerships have fostered an environment of innovation and creativity, leading to the development of her impactful patents.

Conclusion

Atsumi Yamaguchi's contributions to the field of pharmaceuticals through her patents and collaborations highlight her role as a significant inventor. Her work continues to pave the way for advancements in medical treatments, particularly for challenging diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…